← Eichor
Condition: Very High Risk Acute Lymphoblastic Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Very High Risk Acute Lymphoblastic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Orphan Indications for CD19 Redirected Autologous T Cells
Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT04276870Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Phase 2 · 6 location(s) · Hyoung Jin Kang · NCT06257394A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With Firs
Phase 2 · 68 location(s) · Pfizer · NCT05748171Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06247501
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.